Erlotinib enhanced chemoradiotherapy sensitivity via inhibiting DNA damage repair in nasopharyngeal carcinoma CNE2 cells | Zendy

Yunxia Zhang | Zendy; Fang Zhou | Zendy; Jian Zhang | Zendy; Qinzhou Zou | Zendy; Qiang Fan | Zendy; Fuzheng Zhang | Zendy

Open Access

Erlotinib enhanced chemoradiotherapy sensitivity via inhibiting DNA damage repair in nasopharyngeal carcinoma CNE2 cells

Author(s) -

Yunxia Zhang,

Fang Zhou,

Jian Zhang,

Qinzhou Zou,

Qiang Fan,

Fuzheng Zhang

Publication year - 2020

Publication title -

annals of palliative medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.546

H-Index - 19

eISSN - 2224-5839

pISSN - 2224-5820

DOI - 10.21037/apm-19-466

Subject(s) - medicine , nasopharyngeal carcinoma , erlotinib , chemoradiotherapy , cancer research , dna repair , dna damage , oncology , dna , radiation therapy , cancer , epidermal growth factor receptor , genetics , biology

Nasopharyngeal carcinoma (NPC), arising from nasopharynx epithelium, is a rare type of malignant carcinoma that has a specific geographical distribution and a high risk of distant metastases. For most of the diagnosed NPC patients, the total survival rate decreased significantly due to the high local recurrence rate and metastasis rate. Concurrent chemoradiotherapy (CCRT), as routine therapy strategy of NPC, usually accompanies with high-dosage cytotoxic agents and serious toxic side reaction. Therefore, there is an urgent need for update the existing therapy strategies. In this study, we sought to investigate the effects of a combined therapy strategy, erlotinib combined with cisplatin and radiotherapy, on biological characteristics of NPC CNE2 cells and the potential reasons.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research